Amylyx Pharmaceuticals
General Information
Identification Code: 961122450722-80
Website: [object Object]
Entity Form: B.V.
Registration Category: Companies & groups
Registration Date: 7/12/2023
Last Update: 11/13/2023
EP Accredited Number: 0
Mission & Interests
Goals: At Amylyx, our moments are spent in the pursuit of improving the lives of people living with neurodegenerative diseases, and we do so by developing treatment options. Every day presents an opportunity to turn these rapidly progressing diseases into conditions that can be effectively managed – with the end goal of giving people more time with the ones they love.
While the focus of our science is to potentially reduce neuronal cell death, our mission is centered on a commitment to people living with neurodegenerative diseases, their families, and the healthcare professionals who support them. We are working to change the treatment paradigm by developing potential new therapies for the treatment of relentlessly progressive neurodegenerative diseases.
Our aim is to improve the lives of people living with neurodegenerative disorders, including developing therapies etc.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Public health
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: 1) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)
2) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
3) Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)
4) Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products
Communication Activities: None so far, as the advocacy operations of the company in the European Union countries, are still in the early phases of implementation. However, as events and publications take place, they will be listed here.
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Barbara Strozzilaan201
Post Code: 1083HN
City: Amsterdam
Country: NETHERLANDS
Phone: [object Object]
EU Office
Address: Barbara Strozzilaan201
Post Code: 1083HN
City: Amsterdam
Country: NETHERLANDS
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: - We are currently in the process of getting the statutory financial statements prepared and filled. Therefore, we do not have a full financial year closed yet.
- The parent company is Amylyx Pharmaceuticals Inc. based in Boston, United States.
Membership Information
Members10 Percent: 0
Members25 Percent: 0
Members50 Percent: 1
Members75 Percent: 0
Members: 2
Members F T E: 1.5
Structure
Structure Type: Structure
Is Member Of: Not applicable. As a company, we are not affiliated with an organisation, network or association (other than EUCOPE, mentioned in the previous section); nor do we have members.
Organisation Members: The European Confederation of Pharmaceutical Entrepreneurs (https://www.eucope.org)